| Literature DB >> 20226859 |
Hideki Kakutani1, Masuo Kondoh, Rie Saeki, Makiko Fujii, Yoshiteru Watanabe, Hiroyuki Mizuguchi, Kiyohito Yagi.
Abstract
Claudin (CL)-4, a tight junction protein, is overexpressed in some human neoplasias, including ovarian, breast, pancreatic and prostate cancers. The targeting of CL-4 is a novel strategy for tumor therapy. We previously found that the C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) binds to CL-4. In the present study, we genetically prepared a novel CL-4-targeting molecule (DTA-C-CPE) by fusion of C-CPE and diphtheria toxin fragment A (DTA). Although DTA is not toxic to CL-4-expressing L cells, even at 20 microg/ml, DTA-C-CPE is toxic to CL-4-expressing L cells at 1 microg/ml. DTA-C-CPE-induced cytotoxicity was attenuated by pretreatment of the cells with C-CPE but not bovine serum albumin, indicating that DTA-C-CPE may bind to CL-4-expressing L cells through its C-CPE domain. To evaluate the specificity of DTA-C-CPE, we examined its cytotoxic effects in L cells that express CL-1, -2, -4 or -5. We found that DTA-C-CPE was toxic to only CL-4-expressing L cells. Thus, C-CPE may be a promising ligand for the development of cancer-targeting systems. Copyright 2010 Elsevier B.V. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20226859 DOI: 10.1016/j.ejpb.2010.03.003
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571